The purpose of this initiative is to establish an Academic-Industrial Partnership Program to develop new and/or validate existing technologies, methods, and assays for the capture and quantification of tumor associated cells, DNA, RNA, or exosomes in body fluids of patients with early stage disease or
those at high risk; as well as distinguishing cancer from benign disease; or aggressive from indolent cancers.
The precompetitive alliances with industry will harmonize and validate technologies, methods and assays associated with liquid biopsies.